Creation of Porous Fibers That Adsorb Pathogenic Substances of Intractable Diseases
NQ Score
50/100
Key facts
- Creation of Porous Fibers That Adsorb Pathogenic Substances of Intractable Diseases
- Toray Industries, Inc. has developed a technology to control the pore size of polymethyl methacrylate (PMMA) porous fibers over a wide range, from several nanometers to about 1,000 nm. This has led to the creation of porous fibers that can selectively adsorb pathogenic substances related to intractable diseases. This technology offers a new option for blood purification therapy for conditions like autoimmune diseases, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer, which can be an alternative or a complement to conventional treatments.
- Source: PR TIMES
- Date: Sat Mar 28 2026 00:08:15 GMT+0900 (Japan Standard Time)
Direct answer
Toray Industries, Inc. has developed a technology to control the pore size of polymethyl methacrylate (PMMA) porous fibers over a wide range, from several nanometers to about 1,000 nm. This has led to the creation of porous fibers that can selectively adsorb pathogenic substances related to intractable diseases. This technology offers a new option for blood purification therapy for conditions like autoimmune diseases, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer, which can be an alternative or a complement to conventional treatments.
- Citation
- Creation of Porous Fibers That Adsorb Pathogenic Substances of Intractable Diseases (Sat Mar 28 2026 00:08:15 GMT+0900 (Japan Standard Time)), PR TIMES
- Source
- PR TIMES
- Date
- Sat Mar 28 2026 00:08:15 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Toray Industries, Inc. has developed a technology to control the pore size of polymethyl methacrylate (PMMA) porous fibers over a wide range, from several nanometers to about 1,000 nm. This has led to the creation of porous fibers that can selectively adsorb pathogenic substances related to intractable diseases. This technology offers a new option for blood purification therapy for conditions like autoimmune diseases, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer, which can be an alternative or a complement to conventional treatments.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What are the key facts in this article?
- A: Toray Industries, Inc. has developed a technology to control the pore size of polymethyl methacrylate (PMMA) porous fibers over a wide range, from several nanometers to about 1,000 nm. This has led to the creation of porous fibers that can selectively adsorb pathogenic substances related to intractable diseases. This technology offers a new option for blood purification therapy for conditions like autoimmune diseases, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer, which can be an alternative or a complement to conventional treatments.
- Q: What is the direct answer?
- A: Toray Industries, Inc. has developed a technology to control the pore size of polymethyl methacrylate (PMMA) porous fibers over a wide range, from several nanometers to about 1,000 nm. This has led to the creation of porous fibers that can selectively adsorb pathogenic substances related to intractable diseases. This technology offers a new option for blood purification therapy for conditions like autoimmune diseases, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer, which can be an alternative or a complement to conventional treatments.
- Q: What is the source and date?
- A: Source: https://prtimes.jp/main/html/rd/p/000000041.000006853.html | Date: Sat Mar 28 2026 00:08:15 GMT+0900 (Japan Standard Time)